These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 2450638)
1. DNA-synthesis and tumor growth inhibitions by AGGA, a bleomycin-amsacrine hybrid derivative. Bailly C; Pommery N; Henichart JP Cancer Lett; 1988 Jan; 38(3):321-8. PubMed ID: 2450638 [TBL] [Abstract][Full Text] [Related]
2. DNA-binding and DNA-cleaving properties of a synthetic model AGAGLU related to the antitumour drugs AMSA and bleomycin. Bailly C; Kenani A; Helbecque N; Bernier JL; Houssin R; Hénichart JP Biochem Biophys Res Commun; 1988 Apr; 152(2):695-702. PubMed ID: 2452634 [TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological activity and DNA interaction of anilinoacridine and bithiazole peptide derivatives related to the anti-tumor drugs m-AMSA and bleomycin. Morier-Teissier E; Bailly C; Bernier JL; Houssin R; Helbecque N; Catteau JP; Colson P; Houssier C; Hénichart JP Anticancer Drug Des; 1989 Jun; 4(1):37-52. PubMed ID: 2474298 [TBL] [Abstract][Full Text] [Related]
4. Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Haldane A; Finlay GJ; Gavin JB; Baguley BC Cancer Chemother Pharmacol; 1992; 29(6):475-9. PubMed ID: 1568291 [TBL] [Abstract][Full Text] [Related]
5. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. Schneider E; Darkin SJ; Lawson PA; Ching LM; Ralph RK; Baguley BC Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1783-90. PubMed ID: 2850193 [TBL] [Abstract][Full Text] [Related]
6. Molecular interaction between bleomycin and amsacrine in the presence of cupric ions. Bernier JL; Kenani A; Houssin R; Helbecque N; Lohez M; Hecquet B; Hénichart JP J Inorg Biochem; 1986 Aug; 27(4):271-85. PubMed ID: 2427651 [TBL] [Abstract][Full Text] [Related]
7. Comparison of antitumor properties of nitracrine and amsacrine analogs. Mazerska Z; Chołody M; Lukowicz J; Wysocka-Skrzela B; Ledóchowski A Arzneimittelforschung; 1987 Nov; 37(11):1276-81. PubMed ID: 3326605 [TBL] [Abstract][Full Text] [Related]
8. Antitumour activity of substituted 9-anilinoacridines--comparison of in vivo and in vitro testing systems. Baguley BC; Nash R Eur J Cancer (1965); 1981 Jun; 17(6):671-9. PubMed ID: 6895501 [No Abstract] [Full Text] [Related]
9. Chelating, DNA-binding and DNA-cleaving properties of a synthetic model for bleomycin. Kenani A; Lohez M; Houssin R; Helbecque N; Bernier JL; Lemay P; Hénichart JP Anticancer Drug Des; 1987 Aug; 2(1):47-59. PubMed ID: 2452643 [TBL] [Abstract][Full Text] [Related]
10. Intracellular molecular interactions of antitumor drug amsacrine (m-AMSA) as revealed by surface-enhanced Raman spectroscopy. Chourpa I; Morjani H; Riou JF; Manfait M FEBS Lett; 1996 Nov; 397(1):61-4. PubMed ID: 8941714 [TBL] [Abstract][Full Text] [Related]
11. Relationship between DNA-binding and biological activity of anilinoacridine derivatives containing the nucleic acid-binding unit SPKK. Bailly F; Bailly C; Helbecque N; Pommery N; Colson P; Houssier C; Hénichart JP Anticancer Drug Des; 1992 Feb; 7(1):83-100. PubMed ID: 1543529 [TBL] [Abstract][Full Text] [Related]
12. Relationship between the induction of chromosome damage and cytotoxicity for amsacrine and congeners. Ferguson LR; Baguley BC Cancer Treat Rep; 1984 Apr; 68(4):625-30. PubMed ID: 6546899 [TBL] [Abstract][Full Text] [Related]
14. Differential growth inhibition of cultured mammalian cells: comparison of clinical antitumour agents and amsacrine derivatives. Wilson WR; Tapp SM; Baguley BC Eur J Cancer Clin Oncol; 1984 Mar; 20(3):383-9. PubMed ID: 6546720 [TBL] [Abstract][Full Text] [Related]
15. Design of two metal-chelating, DNA-binding models: molecular combinations of bleomycin and amsacrine anti-tumour drugs. Bailly C; Bernier JL; Houssin R; Helbecque N; Hénichart JP Anticancer Drug Des; 1987 Apr; 1(4):303-12. PubMed ID: 2453198 [TBL] [Abstract][Full Text] [Related]
16. Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines. Pommier Y; Covey J; Kerrigan D; Mattes W; Markovits J; Kohn KW Biochem Pharmacol; 1987 Oct; 36(20):3477-86. PubMed ID: 2823823 [TBL] [Abstract][Full Text] [Related]
17. A reassessment of the mechanism of action of 4'-[(9-acridinyl)-amino]methanesulphon-m-anisidide. Marshall B; Ralph RK Eur J Cancer Clin Oncol; 1982 Jun; 18(6):553-7. PubMed ID: 6811280 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and antitumor activity of pyrido-amsacrine analogues and related compounds. Llama E; Del Campo C; Capo M; Anadon M J Pharm Sci; 1993 Mar; 82(3):262-5. PubMed ID: 8450419 [TBL] [Abstract][Full Text] [Related]
19. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Pommier Y; Schwartz RE; Zwelling LA; Kohn KW Biochemistry; 1985 Nov; 24(23):6406-10. PubMed ID: 3002439 [TBL] [Abstract][Full Text] [Related]
20. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine. Baguley BC; Leteurtre F; Riou JF; Finlay GJ; Pommier Y Eur J Cancer; 1997 Feb; 33(2):272-9. PubMed ID: 9135499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]